Related Experiment Video
Updated: Jun 11, 2026
12:47
Inducing Plasticity of Astrocytic Receptors by Manipulation of Neuronal Firing Rates
Published on: March 20, 2014
Aberrant Potassium Handling by Astrocytes and Epileptic Seizures: A Synthetic Update
Jan Albrecht1, Stanisław J Czuczwar2, Władysław Lasoń3
1Department of Neurotoxicology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland.
Acta Physiologica (Oxford, England)
|June 10, 2026
Summary
Astrocytes regulate potassium (K+) levels to prevent seizures in temporal lobe epilepsy (TLE). Impaired K+ transport in astrocytes, particularly involving Kir4.1 and AQP4 channels, contributes to seizure activity in TLE.
Area of Science:
- Neuroscience
- Cell Biology
- Epilepsy Research
Background:
- Extracellular potassium accumulation is a key factor in temporal lobe epilepsy (TLE) seizures.
- Astrocytes are crucial for clearing excess extracellular potassium (K+) from the brain.
Purpose of the Study:
- To review changes in astrocytic K+ transport proteins in TLE.
- To understand the role of astrocytic K+ buffering in seizure pathogenesis.
Main Methods:
- Review of scientific literature on astrocytic K+ transport in TLE.
- Analysis of changes in Kir4.1, AQP4, Na+/K+-ATPase, and K2P channels in TLE models and patients.
Main Results:
- TLE is associated with reduced expression/mislocalization of Kir4.1 and AQP4 in astrocytes.
- Na+/K+-ATPase activity is decreased in TLE, though variable in genetic epilepsies.
- Two-pore domain potassium channels (K2P) show complex, region-dependent changes in astrocytes.
Conclusions:
- Malfunctional astrocytic K+ transport significantly contributes to seizure facilitation in TLE.
- Therapeutic strategies targeting metabolic processes can sometimes restore astrocytic K+ buffering capacity.
Keywords:
K2P channelsKir 4.1Na+/K+‐ATPaseaquaporin‐4astrocytesepileptogenesispotassiumseizurestemporal lobe epilepsyMore Related Videos
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...